Seven Eight Capital’s Kyntra Bio KYNB Stock Holding History

Seven Eight Capital’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-670	Closed	-$719K	–	536
2019 Q4	$719K	Sell	670 -988	-60%	-$1.01M	0.04%	489
2019 Q3	$1.53M	Buy	+1,658	New	+$1.82M	0.08%	354
2019 Q2	–	Sell	-216	Closed	-$294K	–	633
2019 Q1	$294K	Buy	+216	New	+$293K	0.02%	485
2018 Q1	–	Sell	-320	Closed	-$379K	–	424
2017 Q4	$379K	Buy	+320	New	+$401K	0.04%	356

Other funds holding KYNB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Seven Eight Capital's KYNB Position: Q1 2020 in Review

Seven Eight Capital sold out of Kyntra Bio (KYNB) in Q1 2020, closing a stake of 670 shares — an estimated $719K sold.

Seven Eight Capital first reported a position in KYNB in Q4 2017 and held it in 4 quarters. The position peaked at $1.53M in Q3 2019. 187 funds tracked by Wall St. Rank hold KYNB as of Q1 2020.

Seven Eight Capital reported no remaining Kyntra Bio position as of Q1 2020 after selling out during the quarter.
Seven Eight Capital sold 670 Kyntra Bio shares in Q1 2020, an estimated $719K.
Seven Eight Capital first reported a position in Kyntra Bio in Q4 2017 and held it in 4 quarters.
Seven Eight Capital's Kyntra Bio position peaked at $1.53M in Q3 2019.
187 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2020.

Based on Seven Eight Capital's 13F filing for Q1 2020, filed 14 May 2020.